Current WHO Guidelines and the Critical Role of Immunohistochemical Markers in the Subclassification of Non-small Cell Lung Carcinoma (NSCLC): Moving from Targeted Therapy to Immunotherapy

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2017 Nov 30

PMID 29183778

Citations 396

Authors

Lais Osmani

Frederic Askin

Edward Gabrielson

Qing Kay Li

Affiliations

Soon will be listed here.

Abstract

Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in the subtypes of non-small cell lung carcinoma (NSCLC). These findings not only lead to remarkable progress in targeted therapies for lung cancer patients, but also provide fundamental knowledge for the subclassification of NSCLC. More recently, the advancement and clinical application of immunotherapy have reinforced the need for the accurate subclassification of NSCLC. In 2015, the World Health Organization (WHO) and the International Association for the Study of Lung Cancer (IASLC) updated their guidelines for the subclassification of lung cancers. These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted therapy, (3) the unique terminology for subclassifying NSCLC using small biopsy specimens, and (4) the utility of IHC biomarkers in the accurate diagnosis and subclassification of lung cancer. The guidelines have significant prognostic impact on oncologic practice and patient care. In this review, we summarize the current WHO guidelines for the classification of lung cancer, discuss advancements of targeted therapy and immunotherapy, and address the utility and limitation of immunomarkers in the subclassification of NSCLC, as well as the prospective future of the field.

Citing Articles

Effects of circulating RNAs on tumor metabolism in lung cancer (Review).

Zhao P, Zhu Z, Zheng X, Song Y, Chen C, Xu G Oncol Lett. 2025; 29(4):204.

PMID: 40070786 PMC: 11894507. DOI: 10.3892/ol.2025.14950.

STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8 T cell exhaustion.

Li S, Lin J, Huang L, Hu S, Wang M, Sun W Oncogene. 2025; .

PMID: 40025230 DOI: 10.1038/s41388-024-03271-2.

A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment.

Huang Z, Li L, Cai X, Wang S, Jia Y, Li Y Thorac Cancer. 2025; 16(4):e70016.

PMID: 40001320 PMC: 11860276. DOI: 10.1111/1759-7714.70016.

Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy.

Zhong S, Borgeling Y, Zardo P, Jonigk D, Borlak J Clin Transl Med. 2025; 15(3):e70177.

PMID: 39995112 PMC: 11850761. DOI: 10.1002/ctm2.70177.

Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.

Wan X, Zhang C, Kang M, Rossi A, Goto T, Seetharamu N Transl Cancer Res. 2025; 14(1):569-583.

PMID: 39974402 PMC: 11833388. DOI: 10.21037/tcr-2024-2443.

References

Stella G, Luisetti M, Pozzi E, Comoglio P . Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med. 2014; 1(3):251-61. DOI: 10.1016/S2213-2600(13)70009-2. View

Buhrens R, Amelung J, Reymond M, Beshay M . Protein expression in human non-small cell lung cancer: a systematic database. Pathobiology. 2009; 76(6):277-85. DOI: 10.1159/000245893. View

Rekhtman N, Ang D, Sima C, Travis W, Moreira A . Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24(10):1348-59. DOI: 10.1038/modpathol.2011.92. View

Facchinetti F, Marabelle A, Rossi G, Soria J, Besse B, Tiseo M . Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. J Thorac Oncol. 2016; 11(11):1819-1836. DOI: 10.1016/j.jtho.2016.05.027. View

Takamochi K, Ohmiya H, Itoh M, Mogushi K, Saito T, Hara K . Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC Cancer. 2016; 16(1):760. PMC: 5041559. DOI: 10.1186/s12885-016-2792-1. View

Yanagisawa K, Shyr Y, Xu B, Massion P, Larsen P, White B . Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003; 362(9382):433-9. DOI: 10.1016/S0140-6736(03)14068-8. View

Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J . Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005; 353(2):133-44. DOI: 10.1056/NEJMoa050736. View

Lilo M, Allison D, Wang Y, Ao M, Gabrielson E, Geddes S . Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. J Am Soc Cytopathol. 2016; 5(3):123-132. PMC: 5044754. DOI: 10.1016/j.jasc.2015.07.002. View

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

10.

Sharma R, Wang Y, Chen L, Gurda G, Geddes S, Gabrielson E . Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases. Hum Pathol. 2016; 54:8-16. DOI: 10.1016/j.humpath.2016.02.027. View

11.

Fatima N, Cohen C, Lawson D, Siddiqui M . TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol. 2011; 119(2):127-33. DOI: 10.1002/cncy.20135. View

12.

Bishop J, Sharma R, Illei P . Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2009; 41(1):20-5. DOI: 10.1016/j.humpath.2009.06.014. View

13.

Mitsudomi T, Yatabe Y . Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98(12):1817-24. PMC: 11159145. DOI: 10.1111/j.1349-7006.2007.00607.x. View

14.

Nobre A, Albergaria A, Schmitt F . p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol. 2012; 57(1):1-8. DOI: 10.1159/000345245. View

15.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

16.

Gurda G, Zhang L, Wang Y, Chen L, Geddes S, Cho W . Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clin Transl Med. 2015; 4:16. PMC: 4417108. DOI: 10.1186/s40169-015-0057-2. View

17.

Johnson H, Cohen C, Fatima N, Duncan D, Siddiqui M . Thyroid transcription factor 1 and Napsin A double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma. Acta Cytol. 2012; 56(6):596-602. DOI: 10.1159/000339793. View

18.

Brown A, Sirohi D, Fukuoka J, Cagle P, Policarpio-Nicolas M, Tacha D . Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. Arch Pathol Lab Med. 2013; 137(9):1274-81. DOI: 10.5858/arpa.2012-0635-OA. View

19.

Sethi S, Geng L, Shidham V, Archuletta P, Bandyophadhyay S, Feng J . Dual color multiplex TTF-1 + Napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens. Cytojournal. 2012; 9:10. PMC: 3347720. DOI: 10.4103/1742-6413.94570. View

20.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View